{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T16:10:28Z","timestamp":1741882228512,"version":"3.38.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T00:00:00Z","timestamp":1722729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T00:00:00Z","timestamp":1722729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-03254-y","type":"journal-article","created":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T13:02:00Z","timestamp":1722776520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bayesian network analysis of drug treatment strategies for thyroid associated ophthalmopathy"],"prefix":"10.1007","volume":"44","author":[{"given":"Yu","family":"Jinhai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al-Sharabi Abdullah Mohammed","family":"Qassem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Anan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liao","family":"Hongfei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Dequan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,4]]},"reference":[{"issue":"6","key":"3254_CR1","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/ICU.0000000000000529","volume":"29","author":"Z Li","year":"2018","unstructured":"Li Z, Cestari DM, Fortin E (2018) Thyroid eye disease: what is new to know?[J]. Curr Opin Ophthalmol 29(6):528\u2013534. https:\/\/doi.org\/10.1097\/ICU.0000000000000529","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"3254_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","volume":"10","author":"KP Cockerham","year":"2021","unstructured":"Cockerham KP, Padnick-Silver L, Stuertz N et al (2021) Quality of life in patients with chronic thyroid eye disease in the United States[J]. Ophthalmol Ther 10(4):975\u2013987. https:\/\/doi.org\/10.1007\/s40123-021-00385-8","journal-title":"Ophthalmol Ther"},{"issue":"12","key":"3254_CR3","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1089\/thy.2022.0251","volume":"32","author":"HBB Burch","year":"2022","unstructured":"Burch HBB, Perros P, Bednarczuk T et al (2022) Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association[J]. Thyroid 32(12):1439\u20131470. https:\/\/doi.org\/10.1089\/thy.2022.0251","journal-title":"Thyroid"},{"issue":"4","key":"3254_CR4","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L et al (2021) The 2021 European group on graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy[J]. Eur J Endocrinol 185(4):G43\u2013G67. https:\/\/doi.org\/10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"issue":"23","key":"3254_CR5","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e177","volume":"35","author":"HY Ahn","year":"2020","unstructured":"Ahn HY, Lee JK (2020) Intravenous glucocorticoid treatment for Korean graves\u2019 ophthalmopathy patients[J]. J Korean Med Sci 35(23):e177. https:\/\/doi.org\/10.3346\/jkms.2020.35.e177","journal-title":"J Korean Med Sci"},{"issue":"5","key":"3254_CR6","doi-asserted-by":"publisher","first-page":"D27","DOI":"10.1530\/EJE-19-0389","volume":"181","author":"TJ Smith","year":"2019","unstructured":"Smith TJ, Bartalena L (2019) Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?[J]. Eur J Endocrinol 181(5):D27\u2013D43. https:\/\/doi.org\/10.1530\/EJE-19-0389","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"3254_CR7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41562-021-01177-7","volume":"5","author":"JK Kruschke","year":"2021","unstructured":"Kruschke JK (2021) Bayesian analysis reporting guidelines[J]. Nat Hum Behav 5(10):1282\u20131291. https:\/\/doi.org\/10.1038\/s41562-021-01177-7","journal-title":"Nat Hum Behav"},{"issue":"11","key":"3254_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations[J]. Ann Intern Med 162(11):777\u2013784. https:\/\/doi.org\/10.7326\/M14-2385","journal-title":"Ann Intern Med"},{"key":"3254_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials[J]. BMJ 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"3254_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5630","volume":"349","author":"MA Puhan","year":"2014","unstructured":"Puhan MA, Sch\u00fcnemann HJ, Murad MH et al (2014) A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis[J]. BMJ 349:g5630. https:\/\/doi.org\/10.1136\/bmj.g5630","journal-title":"BMJ"},{"issue":"4","key":"3254_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A et al (2020) Teprotumumab for the treatment of active thyroid eye disease[J]. N Engl J Med 382(4):341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"issue":"4","key":"3254_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly GJ, Riedl M, K\u00f6nig J et al (2018) Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial[J]. Lancet Diabetes Endocrinol 6(4):287\u2013298. https:\/\/doi.org\/10.1016\/S2213-8587(18)30020-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"3254_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S2213-8587(21)00238-2","volume":"9","author":"G Lanzolla","year":"2021","unstructured":"Lanzolla G, Sabini E, Leo M et al (2021) Statins for graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial[J]. Lancet Diabetes Endocrinol 9(11):733\u2013742. https:\/\/doi.org\/10.1016\/S2213-8587(21)00238-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3254_CR14","doi-asserted-by":"publisher","first-page":"1140196","DOI":"10.3389\/fendo.2023.1140196","volume":"14","author":"L Li","year":"2023","unstructured":"Li L, Xue J, Guan L et al (2023) Therapeutic outcomes of mycophenolate mofetil and glucocorticoid in thyroid-associated ophthalmopathy patients[J]. Front Endocrinol 14:1140196. https:\/\/doi.org\/10.3389\/fendo.2023.1140196","journal-title":"Front Endocrinol"},{"issue":"2","key":"3254_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N et al (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves\u2019 orbitopathy: a randomized controlled study[J]. J Clin Endocrinol Metab 100(2):422\u2013431. https:\/\/doi.org\/10.1210\/jc.2014-3014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3254_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12020-014-0283-1","volume":"48","author":"G Savino","year":"2015","unstructured":"Savino G, Mandar\u00e0 E, Gari M et al (2015) Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy[J]. Endocrine 48(1):241\u2013247. https:\/\/doi.org\/10.1007\/s12020-014-0283-1","journal-title":"Endocrine"},{"key":"3254_CR17","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0017","author":"L Shen","year":"2022","unstructured":"Shen L, Ye L, Zhu W et al (2022) Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe graves\u2019 orbitopathy[J]. Eur Thyroid J. https:\/\/doi.org\/10.1530\/ETJ-22-0017","journal-title":"Eur Thyroid J"},{"issue":"18","key":"3254_CR18","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG et al (2017) Teprotumumab for thyroid-associated ophthalmopathy[J]. N Engl J Med 376(18):1748\u20131761. https:\/\/doi.org\/10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"issue":"2","key":"3254_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza LB et al (2015) Randomized controlled trial of rituximab in patients with graves\u2019 orbitopathy[J]. J Clin Endocrinol Metab 100(2):432\u2013441. https:\/\/doi.org\/10.1210\/jc.2014-2572","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3254_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1530\/EJE-07-0558","volume":"158","author":"RJ van Geest","year":"2008","unstructured":"van Geest RJ, Sasim IV, Koppeschaar HP et al (2008) Methylprednisolone pulse therapy for patients with moderately severe graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study[J]. Eur J Endocrinol 158(2):229\u2013237. https:\/\/doi.org\/10.1530\/EJE-07-0558","journal-title":"Eur J Endocrinol"},{"key":"3254_CR21","first-page":"922","volume":"38","author":"B Wang","year":"2019","unstructured":"Wang B, Sun J, Hao G et al (2019) (2019) A clinical study on ~(99)Tc-MDP for thyroid-associated ophthalmopathy[J]. Chin J Endemiol 38:922\u2013926","journal-title":"Chin J Endemiol"},{"issue":"4","key":"3254_CR22","doi-asserted-by":"publisher","first-page":"e1653","DOI":"10.1210\/clinem\/dgab824","volume":"107","author":"CC Krieger","year":"2022","unstructured":"Krieger CC, Sui X, Kahaly GJ et al (2022) Inhibition of TSH\/IGF-1 receptor crosstalk by teprotumumab as a treatment modality of thyroid eye disease[J]. J Clin Endocrinol Metab 107(4):e1653\u2013e1660. https:\/\/doi.org\/10.1210\/clinem\/dgab824","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3254_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/IOP.0000000000002563","volume":"40","author":"S Hubschman","year":"2024","unstructured":"Hubschman S, Sojitra B, Ghiam S et al (2024) Teprotumumab and orbital decompression for the management of proptosis in patients with thyroid eye disease [J]. Ophthalmic Plastic Reconstr Surg 40(3):270\u2013275. https:\/\/doi.org\/10.1097\/IOP.0000000000002563","journal-title":"Ophthalmic Plastic Reconstr Surg"},{"key":"3254_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajo.2023.12.001","volume":"263","author":"CJ Hwang","year":"2024","unstructured":"Hwang CJ, Rebollo NP, Mechels KB et al (2024) Reactivation after teprotumumab treatment for active thyroid eye disease[J]. Am J Ophthalmol 263:152\u2013159. https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"3254_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/MNM.0b013e32834121cb","volume":"32","author":"SX Yan","year":"2011","unstructured":"Yan SX, Wang Y, Peng GJ et al (2011) Effects of technetium-99 methylenediphosphonate on cytokine-induced activation of retro-ocular fibroblasts from patients with graves\u2019 ophthalmopathy[J]. Nucl Med Commun 32(2):142\u2013146. https:\/\/doi.org\/10.1097\/MNM.0b013e32834121cb","journal-title":"Nucl Med Commun"},{"key":"3254_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.609895","volume":"11","author":"A Naselli","year":"2020","unstructured":"Naselli A, Moretti D, Regalbuto C et al (2020) Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of graves\u2019 ophthalmopathy to parenteral corticosteroids[J]. Front Endocrinol (Lausanne) 11:609895. https:\/\/doi.org\/10.3389\/fendo.2020.609895","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"3254_CR27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40123-024-00930-1","volume":"13","author":"GC Hsu","year":"2024","unstructured":"Hsu GC, Shih S, Chang F et al (2024) An appraisal of the preventive effect of statins on the development of graves\u2019 ophthalmopathy: a hospital-based cohort study[J]. Ophthalmol Ther 13(6):1499\u20131511. https:\/\/doi.org\/10.1007\/s40123-024-00930-1","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"3254_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s42000-021-00282-6","volume":"20","author":"J Chen","year":"2021","unstructured":"Chen J, Chen G, Sun H (2021) Intravenous rituximab therapy for active graves\u2019 ophthalmopathy: a meta-analysis[J]. Hormones (Athens) 20(2):279\u2013286. https:\/\/doi.org\/10.1007\/s42000-021-00282-6","journal-title":"Hormones (Athens)"},{"issue":"6","key":"3254_CR29","doi-asserted-by":"publisher","first-page":"e1189","DOI":"10.1111\/aos.15074","volume":"100","author":"H Li","year":"2022","unstructured":"Li H, Yang L, Song Y et al (2022) Comparative effectiveness of different treatment modalities for active, moderate-to-severe graves\u2019 orbitopathy: a systematic review and network meta-analysis[J]. Acta Ophthalmol 100(6):e1189\u2013e1198. https:\/\/doi.org\/10.1111\/aos.15074","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"3254_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/bjophthalmol-2018-313697","volume":"104","author":"X Zhou","year":"2020","unstructured":"Zhou X, Zhou D, Wang J et al (2020) Treatment strategies for graves\u2019 ophthalmopathy: a network meta-analysis[J]. Br J Ophthalmol 104(4):551\u2013556. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313697","journal-title":"Br J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03254-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03254-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03254-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:28:03Z","timestamp":1741879683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03254-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3254"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03254-y","relation":{},"ISSN":["1573-2630"],"issn-type":[{"type":"electronic","value":"1573-2630"}],"subject":[],"published":{"date-parts":[[2024,8,4]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"An ethics statement is not applicable because this study is based exclusively on published literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"339"}}